Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model by Chang, Roger L. et al.
Drug Off-Target Effects Predicted Using Structural
Analysis in the Context of a Metabolic Network Model
Roger L. Chang
1, Li Xie
2, Lei Xie
3, Philip E. Bourne
2,3, Bernhard Ø. Palsson
1*
1Department of Bioengineering, University of California San Diego, La Jolla, California, United States of America, 2Skaggs School of Pharmacy and Pharmaceutical
Sciences, University of California San Diego, La Jolla, California, United States of America, 3San Diego Supercomputer Center, University of California San Diego, La Jolla,
California, United States of America
Abstract
Recent advances in structural bioinformatics have enabled the prediction of protein-drug off-targets based on their ligand
binding sites. Concurrent developments in systems biology allow for prediction of the functional effects of system
perturbations using large-scale network models. Integration of these two capabilities provides a framework for evaluating
metabolic drug response phenotypes in silico. This combined approach was applied to investigate the hypertensive side
effect of the cholesteryl ester transfer protein inhibitor torcetrapib in the context of human renal function. A metabolic
kidney model was generated in which to simulate drug treatment. Causal drug off-targets were predicted that have
previously been observed to impact renal function in gene-deficient patients and may play a role in the adverse side effects
observed in clinical trials. Genetic risk factors for drug treatment were also predicted that correspond to both characterized
and unknown renal metabolic disorders as well as cryptic genetic deficiencies that are not expected to exhibit a renal
disorder phenotype except under drug treatment. This study represents a novel integration of structural and systems
biology and a first step towards computational systems medicine. The methodology introduced herein has important
implications for drug development and personalized medicine.
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Introduction
Despite the advantages gained from drug therapy in medicine,
drug development has historically presented an expensive and
frequently perplexing challenge for researchers. Identifying useful
drug targets for treating disease and matching them to chemical
compounds that can elicit the desired effect through drug-target
interaction has been the paradigm for the drug development
process in the era of molecular medicine. However, this approach
has yielded many failed drug treatments and an incomplete
understanding of the consequences of treatments for human
health, even with drugs that have made it to market and been
prescribed for decades. Two major contributing factors that
confound individual molecular target-based drug discovery are
drug off-target binding and the lack of systems-level understanding
of drug response [1]. Adopting a new, systems-based approach to
drug development is therefore a desirable goal in the era of systems
medicine.
The growing wealth of omics data offers a valuable opportunity
for novel approaches in systems medicine but also presents
significant challenges for data integration [2]. Increasingly
sophisticated computational approaches are being developed to
analyze and manipulate omics data in order to gain a greater
understanding of complex biological systems. An algorithm for
identifying and comparing ligand binding sites on protein
structures [3] was recently employed to predict drug off-target
binding sites across the proteome [4]. Such a tool offers unique
capabilities for drug development by providing a comprehensive
survey of uncharacterized drug targets that may participate
directly in drug response, which is likely to be important as
polypharmacology interactions suggest that drug promiscuity is a
predominant property of existing drugs [5].
Biological systems exhibit redundant pathways and synergistic
effects conferring a robustness of phenotype when confronted with
external stimuli. As a result, multi-target drugs are generally more
clinically efficacious than single-target drugs. These facts highlight
the critical importance of studying polypharmacology in a systems
level context [6]. The increasing use of genome-scale metabolic
network models for a variety of applications [7,8] has established
this research platform as a promising means for studying the
emergentpropertiesofcomplexsystems.The publishedapplications
of metabolic models for drug development have thus far focused on
identifying drug targets for antibacterial treatment in such
pathogens as M. tuberculosis [9,10], S. aureus [11,10], H. pylori,a n d
E. coli [10]. However, the human metabolic network reconstruction
(Recon 1) [12] and developed context-specific metabolic modeling
algorithms [13,14] permit human-centered in silico drug studies.
Integrating these structural bioinformatics and human system
modelingtechniquesforapplication indrug developmentrepresents
a first computational step into the era of systems medicine. As an
example of this integrative approach, the results of protein off-target
prediction for the drug torcetrapib [4], a cholesteryl ester transfer
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of renal metabolism.
CETP inhibitors are intended to treat patients at risk for
atherosclerosis and other cardiovascular diseases by raising high-
density lipoprotein cholesterol (HDL-C) and lowering low-density
lipoprotein cholesterol (LDL-C) [15]. Torcetrapib was withdrawn
from phase III clinical trials after a substantial investment of labor
and capital due to its observed side effect of fatal hypertension in
some patients [16]. It has since been of great interest to elucidate
the cause of this side effect in order to avert such failures in the
future and to better define the potential of CETP inhibitors for
treatment [17]. Subsequent studies have provided evidence in
favor of the hypothesis that the cause of this side effect was not due
directly to the mechanism of HDL-C and LDL-C regulation via
CETP inhibition [18]. Instead, it has been suggested that the
hypertensive side effect may result from uncharacterized drug off-
target effects [17]. Two other CETP inhibitors are now under
clinical trial, anacetrapib [18] and JTT-705 [19]. Thus far, studies
have not indicated the same risk of hypertension associated with
the latter two drugs; however, these studies have been limited to
relatively small patient groups lacking in diversity and over
relatively short-term treatment. Even if these alternative CETP
inhibitors do not carry the same adverse side effects, it is still of
value to future drug development to determine the exact
mechanism of torcetrapib’s adverse action. It has been suggested
that off-target effects of torcetrapib lead to increased activity of the
renin-angiotensin-aldosterone-system (RAAS) and thereby hyper-
tension [4,20], but a recent review of the published CETP
inhibitor clinical studies [21] concludes that the effect on blood
pressure is most likely independent of the increase in aldosterone.
Currently the exact cause of the hypertensive side effect of
torcetrapib remains to be unambiguously identified.
The predicted torcetrapib off-targets include many metabolic
enzymes and metabolite transport proteins. Although there are
several mechanisms involved in regulating blood pressure that may
be responsible for the hypertensive side effect, one possible mode is
the renal regulation of blood pressure via metabolite reabsorption
and secretion. The kidneys are the primary organs that filter the
blood and therefore are strong contributors to maintaining a
normotensive state even independent of RAAS function. Thus a
model of renal metabolism was developed as the system context in
which to analyze torcetrapib off-targets and predict drug response
phenotypes. The two best-supported causal off-targets predicted in
this study are prostaglandin I2 synthase (PTGIS), due to decreased
capacity for renal prostaglandin I2 (PGI2) secretion, and acyl-CoA
oxidase 1 (ACOX1), due to decreased capacity for renal citrate and
amino acid reabsorption. Four other predicted off-targets are also
predicted to impact amino acid, glucose, citrate, or bicarbonate
reabsorption. As well, the model predicts no effect on renal
reabsorption or secretion for a number of other predicted off-target
metabolic proteins.
The goal of this study is not only to provide new insight into the
torcetrapib problem but also to reveal the theoretical implications
that this computational systems medicine platform has for drug
development and personalized medicine. Characterizing the
influence that genetic variation has in determining drug response
phenotypes has been recognized as a crucial goal for the future of
drug development [22]. To this end, the renal model was also used
to analyze metabolic disorders resulting from genetic deficiencies
and to identify those deficiencies that may pose additional risks for
drug treatment in select individuals.
Although many of the predictions generated by this approach
are supported by clinical and other experimental evidence that
describe the impact of loss of function for predicted causal off-
targets and genetic deficiencies, the full set of exact metabolic
mechanisms of drug action predicted by our model remain to be
completely validated. While this is seen as a limitation of this study,
it also offers a number of opportunities to experimentally evaluate
promising hypotheses that, if validated, will lead to significant
advancements in developing CETP inhibitors for treatment and
novel insight into certain renal disorders.
Results
Renal Metabolic Model
The approach for context-specific organ modeling proposed in
this study (see Materials and Methods and Figure 1) yielded a renal
metabolic model capturing functions of the kidney for reabsorp-
tion and secretion (Table 1). Many components of the renal
objective function are factors known to be relevant determinants of
blood pressure. However, there is currently incomplete knowledge
about the exact role that some of these components play in blood
pressure regulation. Calcium reabsorption, for example, leads to
vasoconstriction in kidney glomeruli through the action of L-type
and N-type calcium ion channels [23] suggesting a resulting
increase in blood pressure if this mechanism applies across all
vascular tissues. Calcium reabsorption also leads to an inhibition of
renal sodium reabsorption in the proximal tubule [24] suggesting a
blood pressure lowering effect consistent with the observation that
increased dietary calcium also lowers blood pressure [25]. This
highlights the complexity of the effect certain renal reasborptions
have on blood pressure. Nevertheless, the many components
accounted for in the renal objective function enabled explicit
predictions about how system perturbations such as drug
treatment and genetic deficiencies affect the kidney’s ability to
regulate the small molecule content of the blood.
The kidney model included 336 explicitly predicted active
metabolic genes (Table S1) that met criteria for activity as
summarized in Figure 2. The majority, 243 genes, satisfied the
gene expression significance threshold (see Materials and Meth-
ods), although the activity of 58 genes was predicted despite
expression values below the threshold. These genes were activated
Author Summary
Pharmaceutical science is only beginning to scratch the
surface on the exact mechanisms of drug action that lead
to a drug’s breadth of patient responses, both intended
and side effects. Decades of clinical trials, molecular
studies, and more recent computational analysis have
sought to characterize the interactions between a drug
and the cell’s molecular machinery. We have devised an
integrated computational approach to assess how a drug
may affect a particular system, in our study the metabo-
lism of the human kidney, and its capacity for filtration of
the contents of the blood. We applied this approach to
retrospectively investigate potential causal drug targets
leading to increased blood pressure in participants of
clinical trials for the drug torcetrapib in an effort to display
how our approach could be directly useful in the drug
development process. Our results suggest specific meta-
bolic enzymes that may be directly responsible for the side
effect. The drug screening framework we have developed
could be used to link adverse side effects to particular drug
targets, discover new uses for old drugs, identify
biomarkers for metabolic disease and drug response, and
suggest genetic or dietary risk factors to help guide
personalized patient care.
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objectives while remaining minimally inconsistent with gene
expression data and may represent post-transcriptionally upregu-
lated genes. The other 35 genes were predicted to be active
without penalty since no corresponding probesets existed on the
microarray upon which the transcriptomic data was obtained.
Since many of these genes participated in optimal pathways for
achieving renal objectives, it is projected that experimental
measurement would confirm their expression if performed.
The active reactions in the model reflect both the possible
pathways by which the kidney can achieve the specified renal
objectives as well as other functions supported by the gene
expression data. The model included 1587 active reactions (Table
S2), excluding model-based reactions such as objective functions,
exchanges, and demands. Of these active reactions, 333 comprised
a single connected sub-model accounting for all pathways which
could possibly support the specified renal objectives. We refer to
this sub-model as the reduced kidney model (see Table S1 and
Table S2 for the contents of the reduced model and Dataset S1 for
the actual model in SBML format). It should be noted that because
the reduced model included all reactions that can carry flux in
support of the renal objectives, it had the exact same effective flux
state solution space as the full renal model. The reduced kidney
model reactions spanned a broad range of metabolic subsystems
(Figure 3). The largest subsystem consisted of plasma membrane-
spanning transport reactions, which is expected given that this
model captured renal filtration and secretion functions. The
second largest subsystem represented intracellular transport,
Figure 1. Context-specific organ metabolic modeling. Preliminary constraints were imposed upon metabolite exchange fluxes of the full
metabolic network based on coordinated experimental detection of transportable metabolites both in the organ tissue and the biofluids processed
by the organ. Metabolites detected in both biofluid and organ were assumed freely exchangeable in the model, and the remainder of the metabolite
exchanges were tentatively constrained to zero. Organ physiology literature was reviewed to compile an objective function consisting of the
metabolic functions of the organ. Each function was tested for compatibility with the preliminary model. Metabolite exchange, transport, and
demand reactions required to achieve some functions were added to the network, and exchange fluxes for objective metabolites were directionally
constrained in accordance with the literature. Functions not compatible with the model were removed from the overall objective function. The
objective function was then integrated with gene expression data obtained from an organ tissue sample to derive a net, context-specific metabolic
organ model representing the metabolic exchange between the organ and the rest of the body and the metabolic reactions that take place within
the organ to achieve this exchange.
doi:10.1371/journal.pcbi.1000938.g001
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compartments in renal function including the cytosol, endopla-
simic reticulum, Golgi apparatus, and mitochondria. A significant
proportion of the other active subsystems in the reduced kidney
model were involved directly in the metabolism of components of
the renal objective function including carbohydrate, amino acid,
vitamin, lipid, carboxylate, and glutathione metabolism as well as
the urea cycle. These permitted the indirect reabsorption of
metabolites as well as the required synthetic pathways for renal
secretions.
Causal Drug Off-Targets
The integrative framework adopted for predicting causal drug
targets associated with response phenotypes employed both
structural bioinformatics tools as well as modeling techniques of
systems biology (see Materials and Methods and Figure 4). The
Table 1. Renal objective function.
Exchange Class Metabolite Abbreviation Relation to Blood Pressure Reference
secretion hormones Prostaglandin I2 PGI2 vasodilation [60,61]
Prostaglandin D2 PGD2 vasodilation [61]
Calcitriol - lowers blood pressure, Ca2+ reabsorption [62–65]
urea Urea - water/ion counter current system regulating osmolality [66]
cyclic amp Cyclic AMP cAMP important for vaso-dilation/constriction [67]
urate Urate - uknown, but secreted [68]
tryptamine Tryptamine - uknown, but secreted [67]
absorption water Water H2O determinant of blood pressure, ion absorption [66,69,70]
ions/electrolytes Phosphate - determinant of blood pressure [71,72]
Sodium Na+ determinant of blood pressure [70]
Calcium Ca2+ determinant of blood pressure [23–25,63,73,74]
Chloride Cl- determinant of blood pressure [75–77]
Protium H+ determinant of blood pressure [78,79]
Potassium K+ determinant of blood pressure [25,75]
Bicarbonate HCO3- determinant of blood pressure [78]
carboxylates Acetate - unknown, but reabsorbed [80]
Citrate - effects sodium reabsorption [81]
Oxalate - effects sodium reabsorption [82]
glucose D-Glucose - effects sodium reabsorption [80,83–85]
amino acids L-Alanine Ala associated reduction of hypertension/vasodilation [80,85,86]
L-Arginine Arg associated reduction of hypertension/vasodilation [80,85,86]
L-Asparagine Asn associated reduction of hypertension/vasodilation [80,85,86]
L-Aspartate Asp associated reduction of hypertension/vasodilation [80,85,86]
L-Cysteine Cys associated reduction of hypertension/vasodilation [80,85,86]
L-Glutamine Gln associated reduction of hypertension/vasodilation [80,85,86]
L-Glutamate Glu associated reduction of hypertension/vasodilation [80,85,86]
Glycine Gly associated reduction of hypertension/vasodilation [80,85,86]
L-Histidine His associated reduction of hypertension/vasodilation [80,85,86]
L-Isoleucine Ile associated reduction of hypertension/vasodilation [80,85,86]
L-Leucine Leu associated reduction of hypertension/vasodilation [80,85,86]
L-Lysine Lys associated reduction of hypertension/vasodilation [80,85,86]
L-Methionine Met associated reduction of hypertension/vasodilation [80,85,86]
L-Phenylalanine Phe associated reduction of hypertension/vasodilation [80,85,86]
L-Proline Pro associated reduction of hypertension/vasodilation [80,85,86]
L-Serine Ser associated reduction of hypertension/vasodilation [80,85,86]
L-Threonine Thr associated reduction of hypertension/vasodilation [80,85,86]
L-Tryptophan Trp associated reduction of hypertension/vasodilation [80,85,86]
L-Tyrosine Tyr associated reduction of hypertension/vasodilation [80,85,86]
L-Valine Val associated reduction of hypertension/vasodilation [80,85,86]
oligopeptides L-Carnosine - unknown, but reabsorbed [66,87,88]
Glutathione GSH unknown, but reabsorbed [54]
doi:10.1371/journal.pcbi.1000938.t001
Modeling Drug Off-Target Effects
PLoS Computational Biology | www.ploscompbiol.org 4 September 2010 | Volume 6 | Issue 9 | e1000938workflow begins with screening of the entire human structural
proteome, with each subsequent step in the process narrowing the
list of proteins ultimately into a set of targets for which a response
phenotype was predicted upon functional inhibition. The first step
of this process identified putative off-target drug binding sites using
a ligand-binding site structural alignment algorithm (see Materials
and Methods). The 41 predicted metabolic protein off-targets were
the focus of this study (see Table S3), 28 of which had predicted
drug binding sites overlapping with their functional sites.
Simulated inhibition of these targets in the reduced kidney model
(see Materials and Methods) predicted response phenotypes for 6
of the off-target proteins with respect to renal function (Figure 5).
The results of all analysis steps for these 6 off-targets are
summarized in Table 2. The expression of all of these targets
was determined to be the most limiting for their associated
metabolic reactions included in the reduced kidney model (see
Materials and Methods), providing additional evidence supporting
that inhibition of these targets would be expected to have at least
some deleterious impact on those reactions.
The renal response phenotypes for inhibition of two of the
predicted drug off-targets were supported by existing scientific
literature. Simulated PTGIS inhibition completely precluded PGI2
secretion. Based on the relation of renal PGI2 secretion to blood
pressure (see Table 1), this inhibition would be expected to have a
hypertensive effect. Experimental studies confirmed that PTGIS is
associated with essential hypertension in humans [26] and that
transgenic rats highly expressing human PTGIS exhibited
decreased mean pulmonary arterial pressure despite treatment with
monocrotaline to induce hypertension [27]. Inhibition of hydro-
xyacid oxidase 2 (HAO2) in the reduced kidney model led to
reduced glutamate, glycine, and serine reabsorption suggesting a
possible role for HAO2 in the hypertensive side effect following
CETP inhibitor treatment based on the association of amino acid
reabsorption with vasodilation and hypertension (see Table 1).
Figure 2. Summary of gene activity predictions in the full kidney model. The pie chart at bottom represents the Recon1 gene activity
predictions resulting from deriving the kidney model. Genes predicted inactive are those genes with no associated active reaction fluxes in the kidney
model. Genes for which no activity prediction was made are those associated with active reaction fluxes in the kidney model but either are not
representedinthegeneexpression dataorwere not determinedas the genewhoseexpression levelismost limitingforanyassociatedreactionthrough
evaluation of GPR Boolean rules with respect to gene expression data. The slice at top represents genes predicted active in the kidney model.
doi:10.1371/journal.pcbi.1000938.g002
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as a candidate quantitative trait locus for blood pressure in rat
kidney in a study comparing normal to hypertensive rats [29].
Two predicted causal CETP inhibitor off-targets, PTGIS and
ACOX1, exhibited notable binding affinity differences when
comparing docking results for their endogenous substrates to those
for the three CETP inhibitors (Figure 6). The mean predicted
binding affinity of PTGIS for its endogenous substrate prosta-
glandin H2 was weaker than for all three CETP inhibitors
(Figure 6A). Anacetrapib was predicted to have the strongest mean
binding affinity of all four tested molecules for PTGIS and JTT-
705 the weakest of the three drugs. The predicted mean binding
affinity of ACOX1 for its endogenous substrate palmitoyl-CoA
was weaker than for torcetrapib and anacetrapib but stronger than
the affinity of the protein for JTT-705 (Figure 6B). These results
supported potential competitive inhibition of PTGIS and ACOX1
by torcetrapib and anacetrapib, but the predictions suggested a
lesser effect of JTT-705 on ACOX1.
Renal Disorders and Drug Treatment
Similar to the use of the model to test inhibitory effects on drug
targets, the model was also used to predict genetic deficiencies that
lead to renal disorders and drug off-targets that act synergistically
with genetic deficiencies. Simulated gene knockouts predicted to
impact renal objective functions are displayed in Figure S1, Figure
S2 and Table S4. The 118 deficient genes predicted to cause
disorders impacted a variety of renal secretions and absorptions to
varying degrees. Thirteen of these deficiencies predicted total loss
of at least one renal function (see Figure S2).
Some renal disorders were only predicted in the gene-deficient
models in combination with drug treatment, not in the untreated
gene-deficient models or in the normal drug-treated model, and
are referred to in this study as cryptic genetic risk factors. Five such
gene deficiencies were predicted (see Table S4). A deficiency in
CYP27B1, which impacted vitamin D secretion alone, also
exhibited defects in proline reabsorption when combined with
drug treatment in simulation. Defects in three amino acid
transport proteins (SLC7A10, SLC3A1, and SLC7A9) were
predicted to decrease renal glycine reabsorption in combination
with drug treatment along with the disorders predicted in the
absence of drug treatment. The model deficient in the ATP-
binding cassette sub-family C member 1 gene (ABCC1) was
predicted to exhibit a cryptic deficiency in renal phosphate
reabsorption under drug treatment. These predictions are of
special importance because they suggest that these renal
phenotypes would only surface in gene-deficient individuals under
certain conditions, such as when treated with CETP inhibitors.
Model Evaluation and Validation
Multiple evaluations were performed to analyze and validate the
content of the reduced kidney model. The reduced kidney model
effectively predicted activity of significantly expressed metabolic
Figure 3. Reduced kidney model subsystem distribution. The distribution of metabolic reactions predicted to be active in the reduced kidney
model with respect to broad metabolic subsystem categories is shown. The distribution excludes objective function, exchange, and demand
reactions used to perform simulations in the model.
doi:10.1371/journal.pcbi.1000938.g003
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robustly predict activity of highly expressing genes was evaluated
by a five-fold cross validation (see Materials and Methods). Our
approach showed significant recall of the 20% most highly
expressed metabolic genes, p-value =4.57610
222. This observa-
tion is especially notable since the reduced kidney model was not a
global model of kidney metabolism, and the result suggests the
relative importance of the renal functions captured by our model
within the context of total kidney gene activity.
We compared the metabolic gene activity predictions from the
reduced kidney model to the set of significantly expressed genes as
well as to a proteomic dataset derived from normal, healthy
human kidney glomerulus tissue [30] (Figure 7A). A total of 164
genes active in the reduced kidney model, 72% of the predicted
activities, were supported by either significantly expressed mRNA
levels, high-confidence protein detection, or both (see Table S1 for
a detailed list). The remaining 64 gene activities accounted for in
the model include 23 genes with no corresponding microarray
probesets, and therefore not experimentally measured mRNA,
and 41 genes that were determined to express more marginally
below the established significance threshold. Despite a strong
overlap between the transcriptomic and proteomic datasets, there
were also large proportions of both which are unique. This
disagreement may be due to tissue samples being taken from
different kidney sub-tissues in each experiment, absent probesets
on the microarray, or the propensity of mass spectrometry
proteomic experiments to produce false negatives. All of the
counted activities in Figure 7A were included in the full human
Figure 4. Identifying causal genes for drug response pheno-
types and metabolic disorders. First, the human proteome was
screened to identify off-target drug-binding sites. The resulting list of
putative off-targets was filtered to focus on just metabolic proteins.
Then, for each predicted metabolic off-target, the endogenous
functional sites were compared to the predicted drug-binding site to
identify overlap. Off-target proteins for which overlapping binding sites
were identified were considered to be competitively inhibitable by the
drug at the overlapping endogenous functional sites. The functional
consequences of such inhibitions were then tested in an appropriate
context-specific metabolic model. All possible individual gene knock-
outs were also simulated to predict genetic disorders that lead to
functional deficiencies either alone or in combination with drug
treatment. Those off-targets whose inhibition impacted model function
represent causal off-targets predicted to be associated with the drug
response phenotype, and the gene knockouts that impacted model
function represent genetic risk factors for metabolic disorders, which
may lead to amplification of the drug response phenotype.
doi:10.1371/journal.pcbi.1000938.g004
Figure 5. CETP inhibitor renal response phenotypes. Elements of
the color matrix represent the percent of the maximum normal,
untreated renal objective flux achievable by the CETP-inhibitor-treated
normal kidney model. The x-axis corresponds to individual renal
objective functions, and the y-axis corresponds to the predicted drug
off-targets. Metabolite abbreviations are defined in Table 1. Only the
subset of renal objective functions for which a drug response
phenotype was predicted is displayed.
doi:10.1371/journal.pcbi.1000938.g005
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not a global kidney model and that there is potential for expansion
to account for more metabolic functions than those of concern in
this study.
The literature-curated renal functions achievable by the kidney
model were also compared to those achievable by a model derived
from the predictions of Shlomi et al (Figure 7B). While the kidney
model developed in this study was compatible with all 41 curated
renal functions, the predictions of Shlomi et al were only
compatible with 25 functions. This difference in functionality
was due to false negative inactivity predictions made by Shlomi et
al such as inactive urea transport, prostaglandin synthesis, and
ATP synthesis. These results underscore the need to manually
curate automatically generated metabolic network reconstructions
and the advantage of integrating objective functions with context-
specific modeling.
Next, the model was functionally validated by comparing the
gene deficiencies predicted to cause renal disorder to disease
phenotypes in the OMIM database collected from clinical studies.
Twenty known gene deficiencies leading to specific disease
phenotypes were accurately predicted using the model (see Table
S4). Loss of function mutations in the gene encoding 25-
hydroxyvitamin D3-1-alpha hydroxylase (CYP27B1) have been
linked to vitamin D-dependent rickets type I in both human
patients [31] and pigs [32] consistent with the predicted inability of
the gene-deficient model to secrete calcitriol. Hypouricosuria, low
urinary excretion of urate, is a symptom of xanthinuria that is
caused by xanthine dehydrogenase (XDH) deficiency [33], which
is consistent with the deficient model’s inability to excrete urate.
Similarly, hypouricemia, low blood serum urate, is a consequence
of nucleoside phosphorylase (NP) deficiency [34] also predicted in
the model. Deficiency of aromatic L-amino acid decarboxylase
(DDC) leads to increased urinary excretion of 5-hydroxytrypto-
phan [35], which is consistent with the decreased ability to
reabsorb tryptophan and secrete tryptamine predicted through
simulation. Mutations in the mitochondrial cytochrome c oxidase
gene (COX6B1) lead to de Toni-Fanconi-Debre renal syndrome,
whose symptoms include a deficiency in the renal reabsorption of
glucose, amino acids, and bicarbonate [36,37], all of which were
predicted in the model. Deficiencies in seven NADH dehydro-
genase genes all lead to hypoglycemia, confirmed in simulation,
and a decreased ability to oxidize citrate and glutamate [38],
reactions important for indirect renal reabsorption of citrate and
glutamate in the model. Proline dehydrogenase (PRODH)
deficiency causes an inability to oxidize proline in kidney and
other tissues leading to hyperprolinemia that includes increased
urinary excretion of proline as a symptom [39–41], which is also
consistent with the predicted decrease in renal proline reabsorp-
tion. Deficiencies in two genes that take part in the ubiquinol-
cytochrome c reductase complex III (UQCRQ and UQCRB) lead
to proximal tubulopathy, including an inability to reabsorb amino
acids [42]; the gene-deficient model exhibited reduced renal
reabsorption of alanine, glutamate, and proline. Fumarate
hydratase (FH) deficiency leads to defects in glutamate oxidation
in kidney and other tissues [43,44], which is also consistent with
the decreased indirect renal reabsorption of glutamate predicted
by the model. Renal glucosuria, recapitulated in the model, results
from deficiency in a sodium-glucose transporter (SLC5A2) [45].
Dicarboxylicamino aciduria [46] exhibits impaired renal gluta-
mate and aspartate reabsorption and hypoglycemia resulting from
a deficient glutamate transporter (SLC1A1), all symptoms
predicted by the model. Severe dehydration is one symptom
resulting from another deficient transporter (SLC5A1) [47],
confirmed through decreased reabsorption of water in the model.
These results qualitatively describe the ability of our modeling
approach to predict perturbed phenotypic states.
To more rigorously quantify the predictive ability of our model
simulation approach, we performed area under receiver operating
characteristic (AROC) analysis based on not only the above-
mentioned clinical validations of our gene-deficient phenotype
predictions but based on the entire set of such known clinical
phenotypes that could potentially have been investigated using our
model (see Figure S3 and Materials and Methods). The sharp
declines in rates with increasingly stringent classifier ratio thresh-
olds (see Figure S3) reflect the likely low coverage of actual
disorder phenotypes by existing clinical studies. Nevertheless, our
approach performed very well based on this analysis, with an
AROC of 0.7565. Permutation trials resulted in a mean AROC of
0.5112, in close agreement with the expected theoretical randomly
achievable AROC of 0.5. Our approach achieved a significantly
greater AROC than could be expected by chance, p-value
=8.71610
270. Given the relatively low number of actual clinical
negatives available (see Table S5), we also assessed the significance
of our prediction results based purely on the true positive rates
determined through the AROC analysis. The mean true positive
rate of our results in this analysis was 0.2859, significantly greater
than the 0.0215 mean true positive rate obtained randomly, p-
value =3.29610
2127. These analysis results illustrate that our
Table 2. Drug side effect causal off-targets.
Official
Symbol PDB ID Gene ID
SMAP
Prediction
Functional
Site Overlap
Reduced
Model
Reactions
Limited by
Expression
Impacts
Renal
Function in
Simulation
Stronger
Drug
Binding
Affinity
Cryptic Genetic
Risk Factors
References
Supporting
Causal Drug
Target
Prediction
PTGIS 2IAG 5740 66 6 6 6 [26,27]
ACOX1 1IS2
a 51 66 6 6 6
AK3L1 2BBW 205 66 6 6
HAO2 1LTD
a 51179 66 6 6 SLC3A1;SLC7A9;SLC7A10;ABCC1 [28,29]
MT-COI 1V54
a 4512 66 6 6 CYP27B1;ABCC1
UQCRC1 1PP9
a 7384 66 6 6 CYP27B1;ABCC1
aNon-human protein structures were mapped to human genes via bi-directional BLAST against the human proteome and choosing the top hit only if it had E-value
,10
250.
doi:10.1371/journal.pcbi.1000938.t002
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favorable sensitivity and specificity based on actual clinical data
and should hold not only for predicting genetic deficiency
phenotypes but also enzyme inhibition by drugs, which exhibits
a similarly deleterious phenotypic effect.
Parameter Sensitivity Analysis
In order to assess the effects of some of the critical assumptions
made in the model development and simulation procedures, we
performed sensitivity analysis with respect to the predicted renal
disorder phenotypes.
First, we compared the predictive capability of our reduced
kidney model to that of the original, unconstrained human
Recon1 metabolic network. The same approach to simulating
renal disorder states was employed using both models (see
Materials and Methods). We simulated all single gene knock outs
in both models and assessed the renal disorder phenotypes with
respect to each individual component of the renal objective
function based on the ratio of maximum objective flux in the
perturbed state to maximum objective flux in the unperturbed
state. Comparing the results achieved by each model (Figure 8), it
is apparent that although there are a few cases where both models
predict an equal degree of renal disorder given the same genetic
perturbation, the vast majority of disorder phenotypes are more
apparent in the reduced kidney model than in Recon1 alone. In
fact, 427 out of the 608 (71%) disorder phenotypes predicted by
the reduced kidney model showed no degree of disorder relative to
the unperturbed state in Recon1, including 36 of the most severe
phenotypes for which a total loss of renal function was predicted
by the reduced kidney model. These observations display the
predictive ability gained through integration of the gene expression
data via the GIMME algorithm, incorporating metabolomics data
to set exchange constraints, and the addition of six key membrane
transport reactions during the limited function-enabling manual
curation of the model. These reactions involve the transport of
prostaglandins I2 and H2, calcitriol, and carnosine. It should be
noted that the 7 disorders for which Recon1 predicted a more
severe phenotype than the kidney model result directly from the
addition of these transporters in that these transporters have
enabled additional pathways in the kidney model that are absent
in Recon1. All but one of the predictions concerning CETP
inhibitors showed a clearer phenotype in the kidney model as well;
this off-target is PTGIS for which both models predict a complete
loss of function when fully inhibited. Finally, 28 out of the 33
clinically validated phenotypes are predicted more noticeably by
the kidney model, 17 of these showing no disorder phenotype in
Recon1. Overall, this comparison establishes the relative con-
tribution of context-specific modeling in studying disorder and
drug response phenotypes.
Second, we investigated the sensitivity of our drug off-target
response phenotype predictions to the variability of two important
parameters used in our simulations, the system boundary flux
constraint, set as equal fractions of the upper bound on renal
objective fluxes (see Materials and Methods), and the degree of
enzymatic activity inhibition assumed to result from drug
treatment.
The system boundary flux constraint was imposed upon
demand and exchange reactions other than those optimized
during a given simulation. By default we set this constraint
assuming that all allowed boundary fluxes can carry an equal
fraction of the potential maximum renal objective flux. This
assumption was made to allow all pathways that could possibly
contribute to the objective to be used simultaneously in the
optimal flux state, providing the most flexible state while
maintaining maximum sensitivity of our model to additional
system perturbations such as gene deficiencies or drug effects. This
approach was unbiased in that it did not favor any possible
pathway over another in achieving a set objective without
imposing additional constraints, which may not always reflect
biological reality but was the most conservative assumption in the
absence of additional experimental data required to more precisely
set these flux constraints. In our sensitivity analysis, we varied this
parameter between 0 and 1000 flux units, the absolute lower and
upper magnitudes possible in our model, and repeated the
simulations of drug off-target effects. The result of this analysis
Figure 6. Differential causal off-target ligand and drug binding
affinities. (A) Binding affinities of the prostaglandin I2 (prostacyclin)
synthase protein for CETP inhibitors and prostaglandin H2, the
endogenous substrate. (B) Binding affinities of the acyl-Coenzyme A
oxidase 1, palmitoyl protein for CETP inhibitors and palmitoyl-CoA, the
endogenous substrate. Each bar shows the mean binding energy
predicted from docking trials. The standard error is indicated for each
bar along with the number of predicted binding poses.
doi:10.1371/journal.pcbi.1000938.g006
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PLoS Computational Biology | www.ploscompbiol.org 9 September 2010 | Volume 6 | Issue 9 | e1000938Figure 7. Comparative reduced kidney model evaluation. (A) Overlap of gene activity predictions with genes expressing above the
significance threshold. Regions of the diagram are approximately proportional to their associated set sizes. The magenta circle represents the set of
genes predicted active in the reduced kidney model. The cyan circle represents the set of Recon1-associated genes with expression levels above the
significance threshold in the kidney tissue data. The yellow circle represents the set of genes encoding proteins that were detected in normal human
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computed for each simulation (see Materials and Methods). The
coefficient can vary between negative and positive unity and
displays the deviation from a base result, the primary predictions
we have presented in this study. The base result is indicated by a
black star in Figure S4, and the parameter value in this case equals
13.5 flux units.
It is clear from Figure S4 that PTGIS inhibition resulted in the
same renal disorder phenotype regardless of the value of the
system boundary flux constraint parameter. This was because
there was only one pathway in the model by which prostaglandin
I2 could be secreted. Most other disorder phenotype predictions
begin to diverge from the base result around a parameter value of
200 flux units, a fairly permissive value, which shows that the
predictions were fairly robust to variability of this parameter. The
closer to 1000 flux units this parameter was set, the more
completely alternative pathways could compensate for a loss of
function in the simulations. If alternative pathways existed to
achieve a renal function, it was guaranteed that the ability to
predict a disorder phenotype with respect to that function would
be completely lost at the maximum possible parameter value of
1000.
We similarly analyzed the sensitivity of our predictions to
changes in the degree of enzyme inhibition assumed to follow from
drug treatment (Figure S5). For the primary results presented in
this study, we assumed complete inhibition of activity by the drug,
corresponding to a fraction of maximum enzymatic reaction flux
equal to 0 in Figure S5. Similar to the default setting of our system
boundary flux constraint, this default of complete inhibition was
chosen in order to maximize the sensitivity of our model in
detecting disorder phenotypes. Most of the phenotypes were still
detectable to varying degrees with as much as 25% of the
maximum activity of drug targets. The predicted phenotypes
associated with PTGIS, ACOX1, and AK3L1 were especially
robust to variation in degree of inhibition, still exhibiting a
phenotype near 50% of maximum activity. Decreased glucose and
kidney glomerulus tissue. (B) Renal metabolic objectives supported by predicted reaction flux states. The orange circle represents renal metabolic
objectives supported both by the kidney model developed in this study and a kidney model derived from the reaction activity predictions of Shlomi
et al. The red circle represents renal metabolic objectives supported only by the kidney model from this study. Metabolite abbreviations are defined
in Table 1.
doi:10.1371/journal.pcbi.1000938.g007
Figure 8. Predictive ability gained by modeling. The dotted black line is the line y=x for ease of visual comparison. Red marks represent
predictions resulting from inhibition of a predicted CETP inhibitor off-target. Blue marks represent predictions resulting from non-drug-target gene
inhibition. Pluses represent predictions validated in the OMIM database. There are 608 marks in total plotted and exact and partial overlap of some
marks precludes complete visual resolution.
doi:10.1371/journal.pcbi.1000938.g008
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UQCRC1 inhibition exhibited the most sensitivity to variability
in this parameter, although none of the predicted phenotypes
required complete inhibition of the drug target in order to be
detected.
Discussion
A novel approach for making functional predictions of drug
response phenotypes has been introduced that integrates techni-
ques of both structural bioinformatics and systems biology.
Although the current study focused on a specific metabolic system,
the general methodology excluding techniques particular to
metabolic modeling are extensible to other systems such as
signaling or transcriptional regulation. Non-metabolic protein
drug off-targets are predictable using the same structural analysis
tools, and many such off-targets have indeed been predicted as
well for CETP inhibitors [4].
The context-specific organ metabolic modeling strategy em-
ployed in this study represents an improvement upon previous
efforts in this realm. Model development algorithms such as
GIMME [13] or that developed by Shlomi et al, when integrated
with multiple omics datasets, can lead to more biologically realistic
models. It is also of critical importance to include context-specific
metabolic objective functions in the model development process in
order to yield a fully functional and predictive model, as is evident
from the functional comparisons of models performed in this study.
As an early effort at modeling such a context-specific metabolic
system it is important to discuss the limitations of our model.
Although the functional validations presented here are compelling,
currently available clinical data only permits the assessment of a
subset of the predictions possible in the model. Also, the functional
portion of the model, the reduced kidney model, does not and is
not intended to represent a global model of kidney metabolism but
only the specific renal functions studied in this work. As such, our
model does not fully resolve of complexity of the human kidney.
The human kidney fulfills a number of functions not studied here
and is a spatially distributed system across multiple distinct tissue
types. Here we have summarily replaced the various kidney sub-
tissues with a single, net system model. Because we integrated
expression data with curated renal functions that operate across
multiple kidney tissues, it is likely that our model approximates a
superset of the metabolic pathways supporting these functions.
Although we have made several simplifying assumptions in the
model development process, even the current level of model
validation suggests that the gene and reaction content of the model
is fairly accurate and that simulations in this model indeed hold
predictive capability.
The simulation approach taken, optimization of a linear
objective function, does not fully capture the full physiological
role of the kidney. The goal of these simulations was to determine
drug-target effects that may limit the capacity of the kidney to
move towards a homeostatic nominal state from a state of high
blood pressure, thereby decreasing the capacity of the kidney to
lower blood pressure. This strategy is appropriate for the goals of
the current study but would not be appropriate to simulate all
physiological states of interest in the kidney. On a related note, the
choice to define a disorder state based on the ratio of perturbed to
unperturbed maximum achievable renal objective flux demon-
strates a difference in the capacity of the renal function and not
necessarily a precise flux state. Therefore this strategy too is not
appropriate for modeling all physiological states.
The predictions made for CETP inhibitors in this study serve as
illustrative examples of many important implications that this
approach has for drug development and personalized medicine.
Predicted causal off-targets for renal metabolic disorders related to
blood pressure may be responsible in part or full for the clinically
observed hypertensive side effect of torcetrapib. The evidence
resulting from this study suggests that PTGIS and ACOX1 are
both potential causal torcetrapib off-targets, the inhibition of
which may explain the side effect of hypertension. In addition,
AK3L1, HAO2, MT-COI, and UQCRC1 may also play a role in
this side effect as we have predicted, although our docking trials
did not suggest that they are bound as strongly by torcetrapib. The
specific predicted deficiencies in renal function associated with the
drug off-targets can serve as biomarkers to be measured in patients
participating in clinical trials. A positive correlation of these
biomarkers with side effects would lend support to the predictions
of this study and confirm these biomarkers as risk indicators in
future patient treatment. It is important to note that although these
predictions comprise the basis for a renal filtration and secretion-
based hypothesis explaining the hypertensive side effect of
torcetrapib, these results do not refute the hypothesis based on a
RAAS-mediated mechanism. These two hypotheses are not
mutually exclusive and could potentially contribute alternatively
or synergistically to the clinically observed side effects. This
possibility illustrates the major tenet for systems biology: studying a
single protein or even a single pathway is not necessarily sufficient
to explain complex biological phenomena.
Aside from the confirmation that some of our predicted off-
targets are known to be involved in renal disorders, we do not
currently present direct experimental verification that torcetrapib
binds and inhibits the predicted targets and that this inhibition
leads to the predicted response phenotypes. Although this would
be the obvious next step, a retrospective validation is currently
hampered by the availability of the drug and the nature of the
phenotypes both predicted and known. Ideally, relevant physio-
logical studies would be carried out during actual clinical trials,
when a method such as ours would be most useful, in preclinical
and clinical phases of drug development.
The extended structural analysis of causal drug off-targets to
identify differential binding affinities for endogenous substrates
and drug molecules suggests possible differences in drug response
phenotypes across the CETP inhibitors tested. The results suggest
that anacetrapib may potentially lead to a similar response
phenotype to that of torcetrapib, while JTT-705 may not carry the
same adverse effect, at least with respect to the off-targets detailed
in this study. This particular type of analysis may aid in
differentiating between likely response phenotypes expected for
chemically and functionally similar drugs. Results of the
computational pipeline for interaction prediction between proteins
and CETP inhibitors employed in this study, SMAP and docking,
have yet to be confirmed experimentally. Although we are
currently unable to provide direct experimental evidence for the
off-target interaction predictions for this class of drugs, multiple
recent studies have shown experimental support for the general
efficacy of this approach for interaction prediction [48,49].
The predicted renal metabolic disorders with a genetic basis
suggest classes of individuals in which treatment with CETP
inhibitors may pose a higher risk for adverse side effects. These
predictions suggest a likely relationship between participants in
torcetrapib clinical trials exhibiting symptoms of these disorders
and the observed adverse side effects. The concept of cryptic
genetic risk factors for drug treatment introduced in this study
suggests a novel approach to personalized medicine. Should
polymorphisms within these genes be clinically linked to side
effects of drug treatment, the result would comprise a basis for
genetic screening to assess the risk of drug treatment for future
Modeling Drug Off-Target Effects
PLoS Computational Biology | www.ploscompbiol.org 12 September 2010 | Volume 6 | Issue 9 | e1000938patients. Given that these cryptic risk factors are not expected to
elicit the predicted abnormal phenotypes in the absence of drug
treatment, identification of causal polymorphisms through associa-
tion studies could only occur during clinical phase when a
sufficient number of patients could be observed to gain the
statistical power needed to draw significant correlations.
As illustrated above, this approach for in silico drug testing could
become an indispensible tool during the pre-clinical and clinical
phases of new drug development for studying the nature of adverse
side effects. In addition, this platform holds obvious potential for
analyzing drug efficacy in general and identification of potential
beneficent drug sideeffects that may be usefulfor drug repositioning
and could also be easily adapted for studying combinatorial drug
treatment. For a failed drug like torcetrapib, results from this
approach could reinitiate the drug development process, providing
new insight to help target patients who could benefit from the
treatment without the risk of serious adverse side effects.
Materials and Methods
Prediction of CETP Inhibitor Drug Off-Targets
The binding site for CETP inhibitors on the CETP structure
and the predicted off-target binding sites for this class of drug
across the proteome were assumed to be as previously predicted
using the SMAP program [4], which implements the Sequence
Order Independent Profile-Profile Alignment (SOIPPA) algorithm
to identify significant structural similarity to a given ligand-binding
site [3]. The results contained proteins from all organisms
represented in the PDB, not just human structures.
Mapping Off-Target Proteins to the Metabolic Network
In order to integrate the result of drug off-target predictions
with the metabolic network, it was necessary to first map all PDB
structures (http://www.pdb.org) corresponding to human meta-
bolic proteins included in Recon1, downloaded from the BiGG
database, to their respective gene identifiers as represented in
Recon1. The BiGG database requires registration and a password,
which can be requested by visiting (http://bigg.ucsd.edu/bigg/
home.pl). The UniProt ID mapping tool (http://www.uniprot.
org/) was used to map PDB structures corresponding to human
proteins to gene identifiers linked to metabolic reactions in Recon1
accounting for all predicted human metabolic protein drug off-
targets. All non-human predicted metabolic protein drug off-
targets were mapped to their human orthologs using the Basic
Local Alignment Search Tool (BLAST) [50] to perform a bi-
directional BLAST with a mutual best hit criterion. BLAST was
also used to resolve inconsistencies in functional annotation
between Recon1 gene-protein-reaction associations (GPRs) and
gene annotations from the Entrez Gene database (http://www.
ncbi.nlm.nih.gov/sites/entrez?db=gene) with respect to predicted
drug targets, leading to the reannotation of three Recon 1 GPRs.
The overall result of this mapping was that 97 metabolic reactions
in Recon1 were linked to 41 predicted CETP inhibitor off-targets.
Enzyme Inhibition Analysis
The metabolic enzymes predicted as CETP inhibitor off-targets
using SMAP were evaluated to determine potential enzymatic
inhibition by the drug. The predicted drug-binding sites of the
putative off-targets were compared to endogenous ligand-binding
sites from existing PDB protein-ligand complex structures (http://
www.pdb.org) and catalyticsitesfromtheCatalyticSite Atlas(http://
www.ebi.ac.uk/thornton-srv/databases/CSA/). Ligand-binding sites
were defined as amino acid residues lying within 4.5 A ˚ from atoms of
the ligand. Drug-binding sites were defined as residues aligned with
the cholesteryl ester binding sites on the CETP structure using
SMAP. Overlap between endogenous ligand-binding sites and drug-
binding sites was defined by a sharing of any amino acid residues
between the sites. The function of predicted drug targets present in
Recon1 with at least a partial such overlap was considered to be
competitively inhibitable by the drug.
Protein-Ligand Docking
Enzyme substrates were identified from Recon1 reaction
formulas. Certain molecules (H
+,H 2O, O2, phosphate, ferricyto-
chrome C, and ferrocytochrome C) were excluded from docking
trialsduetosizeorstructural challenges prohibiting a useful docking
result for the purposes of binding affinity predictions. All protein
structures used in this study were downloaded from the PDB
(http://www.pdb.org). Three-dimensional structures for endogen-
ous enzyme substrates were downloaded directly from the PDB if
available. If the PDB ligand structure did not exist or was non-
functional for docking, the structure was searched for in PubChem
(http://pubchem.ncbi.nlm.nih.gov/). The subsequently down-
loaded SDF file was converted to PDB format using the ChemAxon
web applet available at the PDB website (http://www.rcsb.org/
pdb/ligand/chemAdvSearch.do). If the three-dimensional ligand
structure could not be found in PubChem, the two-dimensional
structure was derived from the canonical SMILES [51] representa-
tion of the compound available in PubChem and then converted to
a three-dimensional structure in PDB format using the Clean3D
Fine Build tool available through the Marvin web applet (http://
www.chemaxon.com/marvin/sketch/index.jsp). The three-dimen-
sional structures for glycolipids were derived from their KEGG
glycan structures (http://www.genome.jp/kegg/glycan/) using
SWEET-II (http://www.glycosciences.de/spec/sweet2/doc/in-
dex.php).
Protein structures were pre-processed for docking using
AutoDockTools (ADT) version 1.5.2 [52] by adding polar
hydrogen atoms, removing all non-protein molecules from the
PDB structure including water, detergents, and ligands, adding
Kollman charges to the protein and converting it to PDBQT
format. Ligand structures were also prepared using ADT, using
the default method for preparing ligands for docking that adds
hydrogens and charges. The default rotatable bonds were accepted
as well, and the structure was converted to PDBQT format. The
search space for docking was determined visually by centering the
Grid Box in ADT central to the experimentally determined
binding site of the ligand and expanding the dimensions of the
cubic search space to just completely encompass the site.
Docking was performed using AutoDock Vina [53] with default
parameter settings other than the search space specification
described above, and the mean predicted binding affinity from the
set of predicted binding poses was accepted as the true binding
affinity for each docking run. The predicted binding affinities for
endogenous substrates were compared to the affinity of the same
site for the CETP inhibitor drugs in order to make predictions
about differential responses with respect to each of the drugs.
Renal Objective Function
As the preliminary step in modeling human renal function, the
scientific literature was reviewed to compile a list of specific
metabolic functions of the kidney, with a focus on functions
implicated as determinants of blood pressure. This list includes a
number of renal reabsorptions and secretions. Each function in
this list was tested for compatibility with Recon1, downloaded
from the BiGG database (http://bigg.ucsd.edu/bigg/home.pl), by
performing flux balance analysis (FBA) on the fully unconstrained
network optimizing for the given function. Those functions
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flux and are summarized in Table 1. These metabolic functions
were combined with a basic ATP maintenance function to form a
single model reaction that represents the kidney’s ability to filter
the metabolic content of blood with preference for lowering blood
pressure. This model reaction was used as the objective function in
developing the metabolic kidney model and is referred to as the
renal objective function in this study. All stoichiometric coefficients
in this reaction were set equal to one, which is a safe assumption
for the model development step as this only significantly impacts
the magnitude of fluxes through pathways that support each
individual renal objective and not generally whether or not certain
fluxes will be active in the resulting model. For the full renal
objective function reaction to be seen as useful in performing
simulations, more careful balancing of these coefficients based on
experimental evidence would be required. As such, the full renal
objective function was not used in any subsequent simulations with
the model, instead being substituted as an objective by the
reactions representing individual reabsorptions or secretions.
Metabolite exchange and transport reactions needed to achieve
some of the renal functions were also added to the network. It was
observed that Recon1 as a base model could not achieve flux
through certain key renal metabolite reabsorptions: sodium,
calcium, chloride, potassium, and oxalate. These deficiencies were
corrected for by simply adding demand fluxes for these metabolites
in the cytosol model compartment. Demand fluxes were also added
for the remaining kidney reabsorptions and secretions as well to
enable an array of simulations involving individual components of
the renal objective function to be tested. In the case of reabsorption,
this allows for direct reabsorption of metabolites in addition to
indirect reabsorption in which the absorbed metabolite is first
metabolized into other compounds and then reabsorbed into the
blood, as is the primary mechanism of reabsorption for some
metabolites, such as reduced glutathione (GSH) [54].
Kidney Metabolite Exchange Flux Constraints
A preliminary model was created by imposing kidney-specific
exchange flux constraints representing the metabolic exchanges
the kidney carries out with the blood and urine. The preliminary
model was initialized by loading Recon1 into the COBRA
Toolbox [55] and, by default, unbounding all reaction fluxes by
setting them to the default maximum magnitude of 1000 flux
units. Next, the renal objective function was added to the network
as a single reaction. Exchange fluxes for kidney secretion
objectives were constrained to preclude uptake of those metabo-
lites to achieve the renal objective, forcing the model to synthesize
those metabolites in order to secrete them. The resulting
preliminary model included 407 exchange fluxes, only 49 of
which were explicitly unconstrained based on literature-curated
kidney functions and the most basic of metabolic precursor
requirements. The basic metabolic exchanges assumed to take
place include ions and other inorganic compounds.
The Human Metabolomics Database (HMDB) (http://www.
hmdb.ca/) was queried to derive further evidence in support of
allowable exchange fluxes for the kidney. All 407 exchange
metabolites in the preliminary model were searched in HMDB for
experimental detection in specific biofluids and tissues. Those
metabolites detected both in the blood and kidney tissue were
assumed to be freely exchangeable in the kidney model, leading to
78 more explicitly unconstrained exchanges beyond what was
derived from basic and curated kidney-specific metabolic func-
tions. This assumption is based on the kidney’s physiological role
of filtering the blood and the observation that if both the blood and
kidney contain a metabolite, it must either be exchanged between
the two or synthesized separately in both. In the former case, this
data provides evidence of that exchange. In the later case,
although the model might allow a biologically unrealistic
exchange, because the metabolite exists in both blood and kidney,
the impact on simulations using the resulting model should be
merely quantitative in terms of the maximum renal objective
fluxes achievable by the unperturbed model. The integration of
gene expression data in the model development process described
below should reduce the propensity for biologically unsound
metabolic pathway activation that could follow from precursors
introduced by any biologically unsound exchanges. Those
metabolites detected both in the urine and kidney were assumed
to be possible excretions, and exchange constraints were set
accordingly. Excretions determined utilizing the urine metabolo-
mics data mostly showed redundancy in determining exchange
constraints with exchanges determined using blood data or
literature curation with the exception of 4 additional metabolites.
The remaining 276 exchange fluxes for which no evidence was
found to support were tentatively constrained to 0 flux units.
Theresultingpreliminarymodelwasagaintestedfortheabilityto
achieve all kidney-specificmetabolicfunctions.Itwas foundthat this
model could not absorb and metabolize GSH, without also
absorbing oxidized glutathione, the exchange of which was
subsequently unconstrained. Also, L-threonine and L-methionine
could not be absorbed and metabolized in this model without
exchange of 2-hydroxybutyrate and 2-methylcitrate, the exchanges
of which were similarly unconstrained as a corrective measure. The
resulting preliminary model could still achieve all the same renal
objectives as the fully unconstrained model. As a final preliminary
constraining measure, all system effluxes were bound to equal
fractions of the default upper bound on influxes of 1000 flux units;
we term this parameter the system boundary flux constraint. This
was done so that any available direct or indirect reabsorption
pathways could possibly be used to achieve metabolite reabsorption
without biasing the model towards use of any particular pathways
without further evidence. This represents the state of the model just
prior to final processing using the GIMME algorithm. The fitting of
the allowable fluxes to the gene expression data by GIMME
ultimately determined the usable reabsorption and secretion
pathways in accordance with gene expression.
Gene Expression Microarray Data Processing
Two gene expression microarray dataset for normal, healthy kidney
tissue [56] were obtained from the GEO database (http://www.ncbi.
nlm.nih.gov/geo/), accession GSE803. The two background-sub-
tracted datasets were first normalized using a global normalization
factor equal to the sum of probe intensities from the first dataset
divided by the sum of probe intensities from the second dataset to
account for any systematic differences in procedure between the two
experiments. The resulting data were then normalized using the
Lowess method [57] to reduce random noise. The resulting
normalized datasets were then weighted equally as replicates in
determining the final data for integration with the human metabolic
network by taking the mean of the two normalized datasets.
The gene-protein-reaction associations (GPRs) in Recon1 use
Entrez Gene IDs to annotate reactions in the network. To map the
data from the AffyHG-U95 chips to Recon1, all genes included in
Recon1 were mapped to corresponding AffyHG-U95 probesets
using Bioconductor [58] and the most recent chip annotations [59].
A single expression value was then assigned to each gene in Recon1
based on the maximum normalized data value associated with any
of the probesets mapped to a given gene. Next, a single expression
value was assigned to each reaction in Recon1 by evaluating the
Boolean rules in the GPRs with respect to the normalized
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linked by an ANDoperator in a GPR, and the maximum data point
was chosen for genes linked by an OR operator in a GPR.
Finally, a significant expression threshold was established for
subsequent use in the GIMME algorithm. This was done by fitting
the normalized gene expression data to a Gaussian distribution,
estimating the mean and standard deviation of this distribution, and
calculating p-values associated with each data point by subtracting
the cumulative distributionfunction from one. The normalized data
value corresponding to the p-value closest to but not exceeding 0.05
was chosen as the significance threshold; this resulted in a threshold
of 991.3698 for the normalized expression data.
Implementation of GIMME to Obtain Metabolic Kidney
Model
To integrate the renal objective function and kidney gene
expression data with the preliminary model to derive a functional
kidney model, the GIMME algorithm [13] was implemented. The
GIMME algorithm takes a metabolic network model, a gene
expression dataset, and specified required metabolic functions as
input and solves a linear programming optimization to yield the
network flux activity state that maximizes the specified functions
while remaining as consistent as possible with the gene expression
data. The complete renal objective function, the combination of all
functions presented in Table 1, was set as the metabolic objective
with a minimum requirement of 90% of the maximum possible
flux set as a parameter for GIMME in determining the final kidney
model. The reaction expression threshold parameter was set as
described above. GIMME was run with these parameters and the
normalized expression data and preliminary model as inputs. The
resulting reaction activity predictions were used to constrain
metabolic reactions yielding the full kidney model. Subsequently,
the connected sub-graph of this full kidney model, which includes
all functioning reactions possible for achieving the renal objectives,
was isolated and is this portion of the model we focused on for
validation and simulation. We refer to this sub-model as the
reduced kidney model (available in SBML format as Dataset S1).
Validation of Kidney Model Content
Gene activity predictions made when deriving the metabolic
kidney model were compared to the set of expressed genes with
normalized expression values above the significance threshold
described above. Activity predictions were also validated against a
comprehensive proteomics dataset from normal human kidney
glomerulus tissue [30] for overlap with network-associated proteins
detected with high confidence, that is, identified through detection
of two or more peptides.
To evaluate the modeling approachu s e di nt h i ss t u d y ,af i v e - f o l d
cross validation was performed in which the data corresponding to the
most highly expressed 20% of network-associated genes were excluded
before deriving the kidney model. The ability of each approach to
correctly predict the activity of these most highly expressed 20% of
genes was measured from the overlap of predictions with the highly
expressed gene set assuming a hypergeometric distribution, and the
resulting probability was Bonferroni-adjusted.
Simulating Drug Target Effects and Renal Metabolic
Disorders
All predicted metabolic protein drug off-targets were tested in the
kidney model to assess the drug response phenotype caused by
inhibitory effects in this system. Inhibition of metabolic proteins by the
drug was modeled by constraining corresponding reactions catalyzed
by drug targets to 0 flux units. Simulations of the consequences of
these drug effects were performed using FBA as implemented in the
COBRA Toolbox [55] in the MATLAB programming environment.
Each drug target was evaluated with respect to its impact on each
individual renal function to determine if target inhibition by the drug
leads to a renal deficiency relative to the untreated normal kidney
model.This wasdone by optimizing single exchange or demand fluxes
at a time, representing reabsorptions and secretions respectively, out of
the full set listed in Table 1. The cumulative effect of all predicted drug
targets being simultaneously inhibited was also tested against each
individual renal function. Renal secretion fluxes were maximized in
simulation. Renal reabsorption fluxes were set as unbounded and then
maximized while the remainder of allowable uptakes were constrained
to equal fractions of the default maximum magnitude of 1000 flux
units. The additional constraints were imposed for reabsorption
simulations in order to allow the resulting network flux state to include
concurrently active alternative optimal direct and indirect reabsorp-
tion pathways rather than having to identify alternative optimal
pathways by performing multiple simulations.
Single gene deficiencies were also simulated in the kidney model
to assess their effects on renal function and their potential as risk
factors for treatment with CETP inhibitors. Each of the genes
annotated to reactions in Recon1 was knocked-out of the kidney
model and simulations were run using the gene-deficient kidney
model both with and without drug treatment to assess effects on
each individual renal reabsorption and secretion.
Drug response and metabolic disorder phenotypes were assessed
by taking the ratio of maximum gene-deficient, untreated renal
function flux to maximum normal, untreated renal function flux. A
ratio of less than unity indicates a deleterious phenotype. Predicted
metabolic disorder phenotypes were validated against previous
clinical studies as represented in the Online Mendelian Inheritance
in Man (OMIM) database (http://www.ncbi.nlm.nih.gov/omim/).
Cryptic genetic risk factors for drug treatment were also
predicted for which the maximum gene-deficient, untreated renal
objective flux equals the maximum normal, untreated renal
objective flux but the ratio of maximum gene-deficient, drug-
treated renal objective flux to maximum normal, drug-treated
renal objective flux is less than unity.
Parameter Sensitivity Analysis
Sensitivity of our prediction approach to variability in
parameters was performed through repeated simulation in which
we varied the parameter value across the full range of possible
values. We investigated sensitivity with respect to each parameter
independently. A normalized sensitivity coefficient was calculated
as the result of each of these simulations. This coefficient was
calculated by first taking the percent difference in the predicted
outcome relative to a base case, our primary results, and then
dividing it by the maximum possible percent difference.
Area under Receiver Operating Characteristic (AROC)
Analysis
Benchmark data was collected from the OMIM database (http://
www.ncbi.nlm.nih.gov/omim/) by searching for all metabolic dis-
orders related to renal reabsorptions or secretions that are associated
with deficiencies in genes included in the reduced kidney model. The
resulting list of disorders was manually curated using literature
references to identify precisely which metabolic renal reabsorptions
and secretions were impacted. These included not only those renal
functions captured in Table 1, but also other renal exchanges. All
resulting reabsorptions and secretions that can have corresponding
non-zero fluxes under unperturbed conditions in the reduced kidney
model were included in our benchmark data set (see Table S5). Every
phenotype in the benchmark data was investigated through our model
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disorders,taking the ratio of perturbedtounperturbedflux capacities as
a measure of phenotype, where a ratio of one signifies no disorder
phenotype and a ratio of less than one signifies some degree of disorder.
Next, the ratio threshold for classifying normal versus disorder
phenotype was iteratively set to assess the sensitivity and specificity of
our approach for predicting true and false positives across the full range
from zero to one. Note that a threshold of one was used by default for
the main results presented in this study. The true positive rate was
plotted against the false positive rate (see Figure S3), the ROC curve,
and the AROC was computed using the trapezoidal rule for
approximating definite integrals. The statistical significance of our
result was determined by comparison to 100 permutation trials in
which all reaction flux ratios, perturbed to unperturbed, were
randomly shuffled for each simulated gene deficiency and AROC-
analyzed. The permutation trials exhibited true positive and false
negative rates expected for random disorder phenotype classification
(see Figure S3), and thus comprised an appropriate assessment of the
predictive ability of our model simulation approach relative to chance.
One-sample left-tailed student t-tests were performed using an alpha
value of 0.05 to assess the statistical significance of the AROC and
mean true positive rate achieved by our model simulation approach
relative to the permutation results.
Supporting Information
Dataset S1 Reduced kidney model.
Found at: doi:10.1371/journal.pcbi.1000938.s001 (0.50 MB
XML)
Figure S1 Genetic deficiencies causing renal metabolic dis-
orders. Elements of the color matrix represent the percent of the
maximum normal, untreated renal objective flux achievable by the
drug-treated gene-deficient kidney model. The x-axis corresponds
to individual renal objective functions, and the y-axis corresponds
to the individual gene deficiencies represented by their official
gene symbols. Metabolite abbreviations are defined in Table 1,
and official gene symbols are defined in Table S4. Only the subset
of renal objective functions for which a metabolic disorder was
predicted is displayed.
Found at: doi:10.1371/journal.pcbi.1000938.s002 (0.53 MB TIF)
Figure S2 Genetic deficiencies causing renal metabolic disorders
(continued).
Found at: doi:10.1371/journal.pcbi.1000938.s003 (0.48 MB TIF)
Figure S3 ROC curves for gene-deficient phenotype prediction.
The blue line represents the analysis of the predictions of the
model simulations presented in this study. The red lines represent
the analysis of 100 different permutation trials. The dashed black
line is the line y=x.
Found at: doi:10.1371/journal.pcbi.1000938.s004 (0.11 MB TIF)
Figure S4 System boundary flux constraint sensitivity. Only
those drug targets and renal functions are shown for which a
deficient phenotype was predicted. The x-axis is in units of flux.
The black star represents the base case which is presented as our
primary result.
Found at: doi:10.1371/journal.pcbi.1000938.s005 (0.77 MB TIF)
Figure S5 Degree of drug-induced inhibition sensitivity. Only
those drug targets and renal functions are shown for which a
deficient phenotype was predicted. The x-axis values correspond
to the fraction of maximal enzymatic flux achievable in the
untreated simulation, which represents the constraint placed on
associated reactions for each simulation. The black star represents
the base case which is presented as our primary result.
Found at: doi:10.1371/journal.pcbi.1000938.s006 (0.93 MB TIF)
Table S1 Kidney gene activity predictions. A one indicates that
the given gene satisfies the criterion corresponding to that column.
Found at: doi:10.1371/journal.pcbi.1000938.s007 (0.15 MB XLS)
Table S2 Kidney reaction activity predictions. Reactions with at
least one non-zero flux bound are predicted active in the kidney
model. All other reactions are predicted inactive in the kidney
model.
Found at: doi:10.1371/journal.pcbi.1000938.s008 (0.74 MB XLS)
Table S3 Metabolic protein drug target predictions. All
predicted metabolic protein targets for CETP inhibitors were
subject to multiple levels of analysis to determine their possible
causal role in adverse drug response phenotypes. An x indicates a
positive result with respect to column labels representing each level
of analysis. The proteins are sorted by the number of analyses
suggesting a causal role.
Found at: doi:10.1371/journal.pcbi.1000938.s009 (0.03 MB XLS)
Table S4 Summary and validation of gene deficiencies causing
renal metabolic disorders. The complete list of gene deficiencies
predicted to cause renal metabolic disorders is presented. Specific
impacted renal secretions and reabsorptions are also displayed
using metabolite abbreviations as represented in Recon1.
Clinically observed phenotypes validating the association of these
genetic deficiencies with predicted metabolic renal disorders found
in the OMIM database and literature are noted. These validated
predictions are listed first in the table, and the remaining
predictions are sorted by the type of renal disorders caused by
the gene deficiencies in simulation.
Found at: doi:10.1371/journal.pcbi.1000938.s010 (0.05 MB XLS)
Table S5 Clinical gene-deficient renal disorder benchmark data.
The set of clinically-observed gene-deficient renal metabolic
disorder phenotypes collected from the OMIM database are
presented that were used to perform AROC analysis. Clinical
positives are observed disorder phenotypes with respect to specific
metabolite reabsorptions or secretions associated with a gene
deficiency, and clinical negatives are disorder phenotypes that
were clinically confirmed not to occur in association with a gene
deficiency.
Found at: doi:10.1371/journal.pcbi.1000938.s011 (0.03 MB XLS)
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